Metal free percutaneous coronary interventions in all-comers: First experience with a novel sirolimus-coated balloon

Madanchi, Mehdi; Cioffi, Giacomo Maria; Attinger‐Toller, Adrian; Seiler, T.; Somm, Sophie; Koch, Tanja; Tersalvi, Gregorio; Wolfrum, Mathias; Moccetti, Federico; Toggweiler, Stefan; Kobza, Richard; Levine, Molly; Bossard, Matthias; Cuculi, Florim

doi:10.5603/cj.a2022.0106

Cited by 3 publications

(7 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, this study reported a relatively high rate of MACE in ISR lesions (14.9% vs. 4.9% in de-novo lesions) ( 20 ). In addition, we have recently published our early experience with another SCB, the Selution SLR™ (MedAlliance SA, Switzerland), in an all-comer CAD population, which had similar characteristics the current study cohort ( 16 ). There, the MACE rate at 1 year was slightly higher (6.8%).…”

Section: Discussionmentioning

confidence: 71%

Section: Discussionmentioning

confidence: 99%

“…When interpreting our results, one needs to consider that we aim for vigorous lesion preparation, including cutting and/or non-compliant balloons at high pressure, in the majority of DCB cases treated at our site ( 16 , 22 , 23 ). The importance of such a strategy in order to achieve good long-term outcomes following DCB treatment has been shown before ( 5 , 16 , 22 , 23 ). We also liberally use intravascular imaging, namely OCT, in DCB cases, which not only facilitates PCI device selection and DCB sizing, but also the assessment of luminal gain as well as dissections at the end of DCB treatment ( 16 ).…”

Section: Discussionmentioning

confidence: 99%

“…This seems reassuring and may indicate that in the absence or presence of only short segments of newly implanted DES the risk for acute vessel closure or stent thrombosis may be negligible, if there is good flow after SCB usage. When interpreting our results, one needs to consider that we aim for vigorous lesion preparation, including cutting and/or non-compliant balloons at high pressure, in the majority of DCB cases treated at our site (16,22,23). The importance of such a strategy in order to achieve good long-term outcomes following DCB treatment has been shown before (5,16,22,23).…”

Section: Discussionmentioning

confidence: 99%

“…When using DCBs, our internal practice recommendations support the liberal utilization of intravascular imaging (intravascular ultrasound or optical coherence tomography) to plan lesion preparation and DCB sizing. All interventionalists involved in this study almost routinely use cutting balloons and/ or non-compliant (NC) for lesion preparation ( 16 ). This is conform to the 3rd DCB consensus paper ( 5 ).…”

Section: Methodsmentioning

confidence: 99%

See 4 more Smart Citations

Treatment of coronary lesions with a novel crystalline sirolimus-coated balloon

Madanchi,

Attinger-Toller,

Gjergjizi

et al. 2024

Front. Cardiovasc. Med.

Self Cite

View full text Add to dashboard Cite

BackgroundThere is mounting data supporting the use of drug-coated balloons (DCB) not only for treatment of in-stent restenosis (ISR), but also in native coronary artery disease. So far, paclitaxel-coated balloons represented the mainstay DCBs. The SeQuent® crystalline sirolimus-coated balloon (SCB) (B.Braun Medical Inc, Germany) represents a novel DCB, which allows a sustained release of the limus-drug. We evaluated its performance in an all-comer cohort, including complex coronary lesions.MethodsConsecutive patients treated with the SeQuent® SCB were analyzed from the prospective SIROOP registry (NCT04988685). We assessed clinical outcomes, including major adverse cardiovascular events (MACE), target lesion revascularization (TLR), target vessel myocardial infarction (TV-MI) and cardiovascular death. Angiograms and outcomes were independently adjudicated.ResultsFrom March 2021 to March 2023, we enrolled 126 patients and lesions, of which 100 (79%) treated using a “DCB-only” strategy and 26 (21%) with a hybrid approach (DES + DCB). The mean age was 68 ± 10 years, 48 (38%) patients had an acute coronary syndrome. Regarding lesion characteristics, ISR was treated in 27 (21%), 11 (9%) underwent CTO-PCI and 59 (47%) of the vessels were moderate to severe calcified. Procedural success rate was 100%. At a median follow-up time of 12.7 (IQR 12; 14.2) months, MACE occurred in 5 patients (4.3%). No acute vessel closure was observed.ConclusionsOur data indicates promising outcomes following treatment with this novel crystalline SCB in an all-comer cohort with complex coronary lesions. These results require further investigation with randomized trials.

show abstract

Section: Discussionmentioning

confidence: 71%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 3 more Smart Citations

Treatment of coronary lesions with a novel crystalline sirolimus-coated balloon

Madanchi,

Attinger-Toller,

Gjergjizi

et al. 2024

Front. Cardiovasc. Med.

Self Cite

View full text Add to dashboard Cite

show abstract

Drug-coated balloons for coronary artery disease: An updated review with future perspectives

Bhogal,

Hill,

Merdler

et al. 2024

Cardiovascular Revascularization Medicine

View full text Add to dashboard Cite

Revascularization and Medical Therapy for Chronic Coronary Syndromes: Lessons Learnt from Recent Trials, a Literature Review

Pham

Moroni

Gall

et al. 2023

JCM

View full text Add to dashboard Cite

Stable coronary artery disease (CAD) has recently been replaced by a new entity described as chronic coronary syndrome (CCS). This new entity has been developed based on a better understanding of the pathogenesis, the clinical characteristics, and the morbi-mortality associated to this condition as part of the dynamic spectrum of CAD. This has significant implications in the clinical management of CCS patients, that ranges from lifestyle adaptation, medical therapy targeting all the elements contributing to CAD progression (i.e., platelet aggregation, coagulation, dyslipidaemia, and systemic inflammation), to invasive strategies (i.e., revascularization). CCS is the most frequent presentation of coronary artery disease which is the first cardiovascular disease worldwide. Medical therapy is the first line therapy for these patients; however, revascularization and especially percutaneous coronary intervention remains beneficial for some of them. European and American guidelines on myocardial revascularization were released in 2018 and 2021, respectively. These guidelines provide different scenarios to help physicians choose the optimal therapy for CCS patients. Recently, several trials focusing on CCS patients have been published. We sought to synthetize the place of revascularization in CCS patients according to the latest guidelines, the lessons learnt from recent trials on revascularization and medical therapy, and future perspectives.

show abstract

Metal free percutaneous coronary interventions in all-comers: First experience with a novel sirolimus-coated balloon

Cited by 3 publications

References 35 publications

Treatment of coronary lesions with a novel crystalline sirolimus-coated balloon

Treatment of coronary lesions with a novel crystalline sirolimus-coated balloon

Drug-coated balloons for coronary artery disease: An updated review with future perspectives

Revascularization and Medical Therapy for Chronic Coronary Syndromes: Lessons Learnt from Recent Trials, a Literature Review

Contact Info

Product

Resources

About